Guglielmo A, Zengarini C, Agostinelli C, Motta G, Sabattini E, Pileri A
Cells. 2024; 13(7.
PMID: 38607023
PMC: 11012008.
DOI: 10.3390/cells13070584.
Shih B, Ma C, Cortes J, Reglero C, Miller H, Quinn S
J Invest Dermatol. 2024; 144(7):1579-1589.e8.
PMID: 38219917
PMC: 11193653.
DOI: 10.1016/j.jid.2023.12.010.
Xu X, Ma W, Qiu G, Xuan L, He C, Zhang T
Biology (Basel). 2023; 12(10).
PMID: 37887047
PMC: 10603903.
DOI: 10.3390/biology12101337.
Luo Y, Vermeer M, de Haan S, Kinderman P, de Gruijl F, van Hall T
Biochem Biophys Rep. 2023; 35:101535.
PMID: 37664523
PMC: 10470183.
DOI: 10.1016/j.bbrep.2023.101535.
Bordeaux Z, Reddy S, Lee K, Lu W, Choi J, Miller M
Int J Mol Sci. 2023; 24(9).
PMID: 37175780
PMC: 10179468.
DOI: 10.3390/ijms24098075.
Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.
Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M
Healthcare (Basel). 2023; 11(4).
PMID: 36833148
PMC: 9957453.
DOI: 10.3390/healthcare11040614.
modelling of cutaneous T-cell lymphoma: The role of SOCS1.
Luo Y, Vermeer M, de Gruijl F, Zoutman W, Sluijter M, van Hall T
Front Oncol. 2022; 12:1031052.
PMID: 36505769
PMC: 9730277.
DOI: 10.3389/fonc.2022.1031052.
Multifunctionality of Calebin A in inflammation, chronic diseases and cancer.
Brockmueller A, Mueller A, Kunnumakkara A, Aggarwal B, Shakibaei M
Front Oncol. 2022; 12:962066.
PMID: 36185259
PMC: 9523377.
DOI: 10.3389/fonc.2022.962066.
Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park S, Kim L, Park H, Kim H, Heo T
Oncol Rep. 2022; 47(3).
PMID: 35029286
PMC: 8771159.
DOI: 10.3892/or.2022.8263.
Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.
Di Raimondo C, Han Z, Su C, Wu X, Qin H, Sanchez J
Cancers (Basel). 2021; 13(22).
PMID: 34831008
PMC: 8616450.
DOI: 10.3390/cancers13225854.
Mathematical model of STAT signalling pathways in cancer development and optimal control approaches.
Lee J, Lee D, Kim Y
R Soc Open Sci. 2021; 8(9):210594.
PMID: 34631119
PMC: 8479343.
DOI: 10.1098/rsos.210594.
Punicalagin in Cancer Prevention-Via Signaling Pathways Targeting.
Berdowska I, Matusiewicz M, Fecka I
Nutrients. 2021; 13(8).
PMID: 34444893
PMC: 8400644.
DOI: 10.3390/nu13082733.
Omega‑3 polyunsaturated fatty acids inhibit IL‑11/STAT3 signaling in hepatocytes during acetaminophen hepatotoxicity.
Liu Y, Lin J, Chen Y, Li Z, Zhou J, Lu X
Int J Mol Med. 2021; 48(4).
PMID: 34414450
PMC: 8416141.
DOI: 10.3892/ijmm.2021.5023.
JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.
Babu G, Chaudhuri P, Rajappa M, Biswas M, Sansar B, Rajegowda C
Cancer Biol Ther. 2020; 22(1):66-78.
PMID: 33356802
PMC: 7834080.
DOI: 10.1080/15384047.2020.1831371.
The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B, Glen J, Zablotna M, Nowicki R, Sokolowska-Wojdylo M
Arch Dermatol Res. 2020; 313(1):25-31.
PMID: 32270320
PMC: 7806529.
DOI: 10.1007/s00403-020-02062-5.
Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma.
Yang M, Jung S, Chinnathambi A, Awad Alahmadi T, Alharbi S, Sethi G
Biomolecules. 2019; 10(1).
PMID: 31878046
PMC: 7022648.
DOI: 10.3390/biom10010023.
Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H, Qian Y, Wang X, Pi R, Zhao X, Wei X
Cell Prolif. 2019; 53(1):e12719.
PMID: 31778258
PMC: 6985655.
DOI: 10.1111/cpr.12719.
Eupalinolide J Suppresses the Growth of Triple-Negative Breast Cancer Cells Targeting STAT3 Signaling Pathway.
Lou C, Chen Y, Zhang J, Yang B, Zhao H
Front Pharmacol. 2019; 10:1071.
PMID: 31607920
PMC: 6761301.
DOI: 10.3389/fphar.2019.01071.
Epigenetic polypharmacology: A new frontier for epi-drug discovery.
Tomaselli D, Lucidi A, Rotili D, Mai A
Med Res Rev. 2019; 40(1):190-244.
PMID: 31218726
PMC: 6917854.
DOI: 10.1002/med.21600.
miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L, Wu L, Xia H, Bao J, Li Q, Chen X
Cell Cycle. 2019; 18(14):1635-1645.
PMID: 31213131
PMC: 6619951.
DOI: 10.1080/15384101.2019.1629789.